The first-in-class FGFR3 ADC of Qide Pharma commences clinical trials

CAR-T Digest - August 2020

25 Nov 2024: The first-in-class FGFR3 ADC of Qide Pharma commences clinical trials

The U.S. FDA has granted clinical trial approval for GQ1011 (AMB302), a first-in-class ADC targeting fibroblast growth factor receptor 3 (FGFR3) for the treatment of solid tumors
FGFR3 is a key tumor driver in several cancers, including bladder, glioma, ovarian, liver, and cholangiocarcinoma. It is one of the ideal targets for developing antitumor therapies, with mutations in the FGFR3 gene often contributing to cancer progression
GQ1011 is developed through a collaboration between Qide Therapeutics and Aimed Bio. It combines Aimed Bio’s innovative anti-FGFR3 antibody with Qide Pharma’s new topoisomerase payload and advanced coupling and linker technologies, making it a highly stable and homogeneous ADC
Preclinical studies have demonstrated that GQ1011 shows superior efficacy and safety in models of FGFR3-mutated and overexpressed tumors. It has also shown promising synergies when combined with immune checkpoint inhibitors (ICIs), potentially enhancing treatment effectiveness